標題
返回
確定
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Home
NSCLC
#
NSCLC
About 9 search results
Sort by Date
Business
PR Newswire
Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026
WALTHAM, Mass. and HANGZHOU, China
PR Newswire
2026-06-01 19:00
RNK08954
KRAS G12D inhibitor
Ranok Therapeutics
Business
PR Newswire
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups
PR Newswire
2026-06-01 08:15
CS2009
CStone Pharmaceuticals
Trispecific Antibody
Business
PR Newswire
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China
PR Newswire
2026-06-01 08:00
IBI363
TAK-928
Innovent Biologics
Business
PR Newswire
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
SAN FRANCISCO and SUZHOU, China
PR Newswire
2026-06-01 08:00
IBI363
NSCLC
Innovent
Business
PR Newswire
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels
PR Newswire
2026-06-01 08:00
Elisrasib
D3S-001
KRAS G12C inhibitor
Business
PR Newswire
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
SHANGHAI
PR Newswire
2026-05-31 08:09
DZD6008
Golidocitinib
NSCLC
Business
PR Newswire
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
CHENGDU, China
PR Newswire
2026-05-30 22:01
sacituzumab tirumotecan
sac-TMT
OptiTROP-Lung05
Business
PR Newswire
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
CHENGDU, China
PR Newswire
2026-05-30 21:51
Kelun-Biotech
lunbotinib fumarate
RET fusion-positive
Business
PR Newswire
Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
SHANGHAI
PR Newswire
2026-05-29 20:52
ZEGFROVY
Sunvozertinib
EGFR exon20ins